Cargando…
Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells
The bisindole indirubin has been described, more than 30 years ago, as being clinically active in the treatment of human chronic myelocytic leukaemia. However, the underlying mechanism of action has remained unclear. We have reported previously that indirubin and its analogues are potent and selecti...
Autores principales: | Marko, D, Schätzle, S, Friedel, A, Genzlinger, A, Zankl, H, Meijer, L, Eisenbrand, G |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363695/ https://www.ncbi.nlm.nih.gov/pubmed/11161389 http://dx.doi.org/10.1054/bjoc.2000.1546 |
Ejemplares similares
-
Comparison of deregulated expression of cyclin D1 and cyclin E with that of cyclin-dependent kinase 4 (CDK4) and CDK2 in human oesophageal squamous cell carcinoma
por: Matsumoto, M, et al.
Publicado: (1999) -
Nuclear Import of Cdk/Cyclin Complexes: Identification of Distinct Mechanisms for Import of Cdk2/Cyclin E and Cdc2/Cyclin B1
por: Moore, Jonathan D., et al.
Publicado: (1999) -
Indirubin and Indirubin Derivatives for Counteracting Proliferative Diseases
por: Blažević, Tina, et al.
Publicado: (2015) -
Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells
por: Kang, Jian, et al.
Publicado: (2014) -
An Integrative Human Pan-Cancer Analysis of Cyclin-Dependent Kinase 1 (CDK1)
por: Liu, Xuanyou, et al.
Publicado: (2022)